Author: Melnick, Kaitlyn; Dastmalchi, Farhad; Mitchell, Duane; Rahman, Maryam; Sayour, Elias J.
Title: Contemporary RNA Therapeutics for Glioblastoma Cord-id: trsscsn7 Document date: 2021_6_8
ID: trsscsn7
Snippet: Glioblastoma (GBM) is the most common primary brain tumor in adults and is universally lethal with a median survival of less than two years with standard therapy. RNA-based immunotherapies have significant potential to establish a durable treatment response for malignant brain tumors including GBM. RNA offers clear advantages over antigen-focused approaches but cannot often be directly administered due to biological instability. This review will focus on utilization of RNA dendritic cell vaccine
Document: Glioblastoma (GBM) is the most common primary brain tumor in adults and is universally lethal with a median survival of less than two years with standard therapy. RNA-based immunotherapies have significant potential to establish a durable treatment response for malignant brain tumors including GBM. RNA offers clear advantages over antigen-focused approaches but cannot often be directly administered due to biological instability. This review will focus on utilization of RNA dendritic cell vaccines and RNA nanoparticle therapies in the treatment of GBM. RNA-pulsed dendritic cell vaccines have been shown to be safe in a small phase I clinical trial and RNA-loaded nanoparticle vaccines will soon be underway in GBM patients (NCT04573140).
Search related documents:
Co phrase search for related documents- activator signal transducer and adaptive response: 1, 2, 3, 4, 5
Co phrase search for related documents, hyperlinks ordered by date